CJC-1295 NO DAC Ipamorelin Peptide Blend Research – Complete Guide

Table of Contents

• Quick Facts
• What is CJC-1295 NO DAC Ipamorelin Blend?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Growth hormone secretion, musculoskeletal repair, metabolic regulation, body composition, bone density, neuroprotection
• First Developed: CJC-1295 developed in early 2000s; Ipamorelin developed by in the late 1990s
• Combined Molecular Weight: CJC-1295 NO DAC: 3,367.9 g/mol + Ipamorelin: 711.85 g/mol
• Research Status: CJC-1295 has completed Phase I/II human trials; Ipamorelin has limited published human pharmacokinetic data; blend research primarily preclinical
• Key Mechanisms: GHRH receptor activation (CJC-1295 NO DAC); ghrelin receptor (GHS-R1a) activation (Ipamorelin); synergistic amplification of pituitary GH release
• Published Studies: CJC-1295: multiple peer-reviewed clinical studies; Ipamorelin: preclinical and limited early-phase human data; combination studies: largely preclinical and theoretical
• Clinical Trial Status: CJC-1295 (DAC variant): Phase I/II completed; Ipamorelin: early-phase human pharmacokinetic trials; blend-specific human trials: not completed
• Regulatory Classification: Research use only; not approved for human therapeutic use by FDA or EMA

What is CJC-1295 NO DAC Ipamorelin Blend?

CJC-1295 NO DAC is a synthetic 29-amino acid peptide analog of growth hormone-releasing hormone (GHRH), the hypothalamic signal that prompts the pituitary gland to release growth hormone. The compound incorporates four strategic amino acid substitutions compared to the native GHRH sequence, improving its resistance to enzymatic breakdown while preserving potent receptor binding. The "NO DAC" designation distinguishes it from a longer-acting variant that uses Drug Affinity Complex technology to extend half-life; without DAC, this peptide acts over hours rather than days, producing a secretion pattern that more closely mirrors natural physiology.

Ipamorelin is a synthetic pentapeptide originally developed by in the late 1990s. Unlike CJC-1295 NO DAC, it does not mimic GHRH. Instead, it activates the ghrelin receptor, a distinct pathway that also stimulates pituitary growth hormone release. Ipamorelin is notable among growth hormone secretagogues for its selectivity: it triggers GH release without substantially affecting cortisol, prolactin, or adrenocorticotropic hormone (ACTH), which are common off-target effects of less selective compounds in the same class.

Scientists study these two peptides together because they engage entirely different receptor systems to produce the same downstream outcome: increased GH secretion from the pituitary gland. CJC-1295 NO DAC creates a sustained hormonal environment favorable to GH release, while Ipamorelin generates a rapid, high-amplitude GH pulse. The combination produces GH release patterns that are larger in magnitude and longer in duration than either peptide alone, while still maintaining the pulsatile character of natural GH secretion rather than creating the continuous, non-physiological stimulation associated with exogenous GH administration.

Research interest in this blend spans growth hormone physiology, musculoskeletal biology, metabolic regulation, and aging. Most evidence comes from animal models and cell culture studies. Clinical data exists for CJC-1295 (primarily the DAC version) and for Ipamorelin individually, but blend-specific human trials have not been completed. Both peptides are classified as research-use-only compounds and are not approved for human therapeutic application.

Molecular Structure and Core Properties

Chemical Structure and Specifications

CJC-1295 NO DAC Molecular Structure

CJC-1295 NO DAC Technical Specifications

Ipamorelin Molecular Structure

Ipamorelin Technical Specifications

Key Structural Features

CJC-1295 NO DAC contains four substituted amino acids at positions 2, 8, 15, and 27 relative to native GHRH 1-29. Position 2 replaces alanine with D-alanine, conferring resistance to dipeptidyl peptidase-IV (DPP-IV), the enzyme responsible for rapid degradation of the native GHRH sequence. The other substitutions improve receptor binding affinity and overall metabolic stability. The absence of DAC technology means the peptide does not bind albumin for extended circulation; its plasma half-life ranges from 30 minutes to 2 hours, enabling dose-by-dose control over GH stimulation timing.

Ipamorelin incorporates two non-natural amino acids: aminoisobutyric acid (Aib) at position 1 and D-2-naphthylalanine (D-2-Nal) at position 3. These structural features create selective binding geometry for the GHS-R1a ghrelin receptor while minimizing interactions with other pituitary hormone receptors. This selectivity distinguishes Ipamorelin from earlier ghrelin mimetics such as GHRP-2 and GHRP-6, which produce more pronounced cortisol and prolactin responses alongside GH release.

The structural divergence between the two peptides underpins the rationale for blend research. CJC-1295 NO DAC operates through an entirely different receptor class than Ipamorelin, meaning co-administration targets two independent intracellular signaling cascades simultaneously rather than saturating a single pathway.

Mechanisms of Action Being Investigated

The CJC-1295 NO DAC and Ipamorelin blend activates growth hormone secretion through two distinct receptor systems in the anterior pituitary gland. These pathways converge on the same somatotroph cells that produce GH but use different second messenger systems, creating complementary and potentially synergistic stimulation.

GHRH Receptor Activation by CJC-1295 NO DAC

CJC-1295 NO DAC binds to GHRH receptors expressed on somatotroph cells in the anterior pituitary. Receptor binding triggers conformational changes that activate heterotrimeric G-proteins, primarily Gs. Activated Gs stimulates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates transcription factors and ion channels involved in GH gene expression and secretion.

The four amino acid substitutions in CJC-1295 NO DAC increase binding affinity to the GHRH receptor compared to the native peptide while resisting DPP-IV degradation. This results in sustained receptor occupancy and prolonged downstream signaling. In human studies using the DAC version, single doses elevated plasma GH levels 2- to 10-fold for up to 6 days, and IGF-1 remained elevated for 9 to 11 days [1]. The NO DAC version produces a shorter but still multi-hour sustained effect, enabling pulsatile dosing protocols that maintain the episodic character of natural GH release.

Ghrelin Receptor Activation by Ipamorelin

Ipamorelin acts as a selective agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), which is the receptor normally activated by the endogenous hunger hormone ghrelin. Receptor binding activates Gq/11 proteins, stimulating phospholipase C (PLC) to cleave phosphatidylinositol 4,5-bisphosphate into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). The calcium surge in somatotroph cells directly triggers GH-containing secretory vesicles to fuse with the cell membrane and release their contents.

Ipamorelin achieves this GH release with minimal activation of other pituitary cell types. Unlike GHRP-2 and GHRP-6, which elevate cortisol and prolactin at research-relevant doses, Ipamorelin does not significantly stimulate ACTH, cortisol, FSH, or TSH release [2]. This selectivity makes it a useful tool for studying GH-specific effects without confounding changes in the broader hormonal environment. Peak GH plasma concentrations occur within 40 to 60 minutes of administration, followed by a return toward baseline within approximately 2 hours [3].

Complementary Signaling and Synergistic Amplification

The cAMP pathway activated by CJC-1295 NO DAC and the calcium mobilization pathway activated by Ipamorelin converge inside somatotroph cells, activating distinct but cooperative mechanisms that both promote GH vesicle exocytosis. Because neither peptide fully saturates either pathway at physiological doses, co-administration engages both simultaneously, producing GH release that exceeds the additive sum of each compound alone.

Animal studies and pharmacological modeling suggest the combination produces 3- to 5-fold greater GH release compared to either peptide individually [4]. A 2025 pharmacological review reported a 7.5-fold pulse amplitude increase with the combination approach [5]. CJC-1295 NO DAC elevates the baseline GH secretory environment over several hours, while Ipamorelin superimposes a rapid, high-amplitude pulse within that window. The result is a secretion pattern with both higher peaks and a more sustained inter-pulse GH elevation.

IGF-1 Upregulation Through Downstream Signaling

GH released by both pathways enters systemic circulation and binds to growth hormone receptors on hepatocytes in the liver. This activates the JAK-STAT5 signaling pathway, increasing transcription of the IGF-1 gene. Elevated plasma IGF-1 mediates many of the anabolic effects observed in animal research, including effects on muscle tissue, bone, and adipose metabolism. IGF-1 also participates in negative feedback, reducing hypothalamic GHRH output and increasing somatostatin release to prevent GH excess [6].

CJC-1295 administration has elevated IGF-1 by 1.5- to 3-fold in human studies, with concentrations remaining above baseline for 9 to 11 days after a single dose and up to 28 days with repeated dosing [1]. Ipamorelin contributes to sustained IGF-1 elevation when administered alongside CJC-1295 NO DAC by maintaining higher GH pulse amplitudes throughout the dosing window.

Neuropeptide Y Modulation by Ipamorelin

Ipamorelin uniquely regulates neuropeptide Y (NPY), a signaling molecule with roles in appetite regulation, pain modulation, and stress response. Unlike other ghrelin receptor agonists that substantially activate NPY pathways and stimulate appetite, Ipamorelin’s receptor binding profile produces minimal NPY-driven appetite signaling. This characteristic reduces confounding variables in research examining GH-specific biological effects separately from appetite or stress hormone changes [2].

Major Areas of Research

The CJC-1295 NO DAC and Ipamorelin blend attracts research interest across multiple biological systems, all stemming from the downstream effects of amplified GH and IGF-1 signaling.

Growth Hormone Secretion and Pituitary Function Studies

Growth hormone secretion research represents the foundational application area for this blend. Studies examine how dual-pathway stimulation affects GH pulse amplitude, frequency, and duration compared to single-peptide approaches.

CJC-1295 (DAC version) produced dose-dependent GH and IGF-1 increases in a human Phase I/II study of 64 healthy adults across a broad age range. Single intravenous or subcutaneous doses at 30 to 60 mcg/kg elevated GH 2- to 10-fold within 2 hours, with IGF-1 remaining elevated for 9 to 11 days [1]. A companion study confirmed that pulsatile GH secretion persisted even during sustained CJC-1295 stimulation, a critical finding demonstrating that receptor desensitization does not abolish physiological pulsatility [7].

Ipamorelin studies in healthy subjects show biologically effective GH peaks within one hour of administration, without significant effects on cortisol or prolactin [3]. Picomolar to micromolar concentrations produced dose-dependent GH release from rat anterior pituitary cell cultures, establishing the mechanistic basis for in vivo observations [2].

Key Research Highlights:

• 2- to 10-fold GH increases with single CJC-1295 doses in human Phase I/II study
• Pulsatile secretion maintained during sustained CJC-1295 stimulation
• Ipamorelin GH specificity confirmed: no significant cortisol or prolactin elevation at effective doses
• Combination produces 3- to 5-fold greater GH release than either peptide alone in animal models

Musculoskeletal Research Applications

Musculoskeletal research investigates how GH and IGF-1 elevation driven by this blend affects bone formation, muscle growth, and connective tissue repair. These studies use animal models of aging, glucocorticoid-induced suppression, and injury to examine potential applications.

Ipamorelin demonstrated dose-dependent increases in longitudinal bone growth in rat models, increasing growth plate activity from approximately 42 micrometers per day in vehicle controls to 52 micrometers per day at the highest dose tested [8]. A follow-up study showed Ipamorelin counteracted glucocorticoid-induced bone formation suppression in adult rats, partially restoring bone mineral content after prednisolone administration [9]. These findings are relevant to research on steroid-associated osteoporosis and bone loss in catabolic states.

Skeletal muscle research documents IGF-1-mediated activation of muscle satellite cells and protein synthesis pathways downstream of GH stimulation. Animal studies using GH-deficient rodent models show improvements in lean body mass and reductions in fat mass following secretagogue administration, though effect sizes vary considerably with study design [10].

Key Research Highlights:

• Dose-dependent bone growth rate increases with Ipamorelin in rat models
• Counteraction of glucocorticoid-induced bone suppression demonstrated
• IGF-1-mediated muscle protein synthesis activation documented in rodent models
• Lean mass improvements observed in GH-deficient animal models

Metabolic Regulation and Body Composition Studies

Metabolic research examines how elevated GH and IGF-1 alter fat metabolism, glucose handling, and energy expenditure. GH promotes lipolysis in adipose tissue and modulates insulin sensitivity, creating complex metabolic interactions that researchers study to understand both the potential and the limitations of GH secretagogue approaches.

Animal studies demonstrate that sustained GH elevation through secretagogue administration reduces visceral fat accumulation while supporting lean tissue maintenance [10]. These effects parallel what is observed with exogenous GH in research models, suggesting that stimulating endogenous GH release through pituitary pathways produces metabolically similar outcomes. Ipamorelin’s lack of significant appetite stimulation compared to other ghrelin mimetics simplifies the interpretation of body composition effects by reducing confounding changes in caloric intake [2].

Nitrogen metabolism studies show Ipamorelin may reduce catabolism of nitrogen-containing compounds, decreasing urea cycle enzyme expression and restoring nitrogen balance in catabolic animal models. A 2025 pharmacological review reported approximately 20% reduction in catabolic nitrogen urea synthesis (CUNS) with Ipamorelin treatment in these models [5].

Key Research Highlights:

• Visceral fat reduction with maintained lean mass in secretagogue-treated animal models
• Ipamorelin-specific reduction in catabolic nitrogen excretion
• Lipolysis stimulation documented as downstream GH effect in adipose tissue models
• Metabolic effects distinguish Ipamorelin from appetite-stimulating ghrelin mimetics

Aging and Age-Associated GH Decline Research

Age-related research examines whether GH secretagogue blends can restore GH secretion patterns that decline with normal aging, a phenomenon termed somatopause. GH pulse amplitude and IGF-1 concentrations decline progressively from young adulthood, and researchers study secretagogue approaches as tools for investigating the biology of this decline.

CJC-1295 human studies enrolled adults spanning ages 21 to 61, demonstrating consistent GH and IGF-1 responses across age groups at the same doses [1]. This age-independent response pattern is noted because GH secretagogues work by amplifying pituitary responsiveness, which remains partially preserved even in older adults whose hypothalamic GHRH output has declined. Animal studies of aging rodents show improvements in GH pulse parameters with secretagogue treatment, providing mechanistic context for the human observations [11].

The blend research rationale in aging contexts rests on the complementary receptor coverage: GHRH-pathway stimulation by CJC-1295 NO DAC addresses declining hypothalamic GHRH signaling, while Ipamorelin’s ghrelin pathway provides an independent stimulus that does not depend on intact hypothalamic function.

Key Research Highlights:

• Consistent GH and IGF-1 responses across age groups 21-61 in human CJC-1295 study
• Animal studies document GH pulse restoration in aging rodent models
• Dual-pathway rationale: each peptide provides alternative GH stimulation when one pathway declines
• IGF-1 sustained for up to 28 days with repeated CJC-1295 dosing

Neuroprotection and Cognitive Function Research

Neurological research investigates GH and IGF-1 effects on brain tissue, cognitive function, and neuroprotection. Both GH receptors and IGF-1 receptors are expressed throughout the brain, and preclinical studies document roles for these signals in neurogenesis, synaptic plasticity, and neuronal survival.

IGF-1 elevation following GH secretagogue administration crosses the blood-brain barrier and activates neuroprotective signaling in animal models of neurodegeneration and ischemia. Studies using GH-deficient animal models show cognitive performance improvements following IGF-1 restoration, suggesting that GH secretagogue-driven IGF-1 elevation may be a useful tool for studying the neurotrophic roles of this axis [12].

Ipamorelin’s regulation of neuropeptide Y adds another dimension to its potential neurological research applications. NPY plays roles in anxiety regulation, stress response, and pain processing, and selective modulation through Ipamorelin’s receptor profile enables investigation of these pathways without the full spectrum of ghrelin-driven effects [2].

Key Research Highlights:

• IGF-1 brain penetration and neuroprotective signaling documented in preclinical models
• Cognitive improvements in GH-deficient animal models following IGF-1 restoration
• Neuropeptide Y modulation by Ipamorelin provides tool for studying stress and pain pathways
• GH receptor expression in brain tissue establishes direct neurological targets for secretagogue research

Wound Healing and Tissue Repair Research

GH and IGF-1 both promote tissue repair processes, and secretagogue-driven elevation of these signals is studied in wound healing and recovery models. IGF-1 stimulates fibroblast proliferation, collagen synthesis, and epithelial cell migration, all key components of wound closure and tissue remodeling.

Animal studies applying GH secretagogues in wound healing contexts document accelerated closure rates and improved tissue organization compared to controls [13]. The mechanisms involve IGF-1-driven activation of the PI3K-Akt pathway in fibroblasts and epithelial cells, promoting both proliferation and survival during the repair process. Research into the blend’s wound healing effects remains limited compared to individual peptide applications, with most evidence extrapolated from GH and IGF-1 biology rather than direct blend studies.

Key Research Highlights:

• IGF-1-driven fibroblast proliferation and collagen synthesis documented
• Accelerated wound closure in animal models following GH secretagogue administration
• PI3K-Akt pathway activation identified as key mediator of IGF-1 tissue repair effects
• Direct blend wound healing studies limited; evidence largely extrapolated from GH/IGF-1 research

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

CJC-1295 NO DAC requires parenteral administration for systemic activity; its large molecular size and peptide structure prevent meaningful oral bioavailability. Subcutaneous and intravenous routes have been studied in preclinical and clinical contexts. Following subcutaneous injection in human research subjects, CJC-1295 (DAC version) reached peak plasma concentrations within 1 to 2 hours [1]. The NO DAC version reaches peak concentrations more rapidly due to its shorter half-life, with plasma levels rising within 15 to 30 minutes and declining within 2 hours.

Ipamorelin similarly requires injection for research applications. Its smaller molecular size (711.85 g/mol) allows for more rapid tissue distribution following subcutaneous administration. Peak GH stimulation occurs within 40 to 60 minutes of injection, consistent with rapid plasma concentration peaks followed by GH secretory response [3].

Distribution and Metabolism

CJC-1295 NO DAC distributes systemically following absorption. The four amino acid substitutions confer resistance to DPP-IV, the primary enzyme responsible for cleaving the native GHRH N-terminus, but the peptide remains susceptible to other circulating proteases. Plasma half-life ranges from 30 minutes to 2 hours in animal models and limited human pharmacokinetic data. This duration is substantially shorter than the DAC version’s 6- to 8-day half-life but still long enough to sustain GH receptor signaling through a multi-hour window.

Ipamorelin’s plasma half-life is approximately 2 hours in rodent models and early human studies. The non-natural amino acids at positions 1 and 3 slow degradation by common peptide-cleaving enzymes, contributing to this stability. Ipamorelin distributes across most tissues and has demonstrated central nervous system penetration in rodent studies, consistent with its ability to modulate neuropeptide Y and act on centrally located GHS-R1a receptors.

Delivery Methods Under Investigation

• Subcutaneous injection: Primary route in most animal and human studies for both peptides; provides predictable absorption kinetics and avoids first-pass metabolism
• Intravenous injection: Used in some human pharmacokinetic studies for CJC-1295; provides immediate bioavailability and precise dose control
• Intraperitoneal injection: Common in rodent research; enables rapid systemic distribution for acute dosing studies
• Intranasal delivery: Under investigation for Ipamorelin in central delivery research; limited published data

Excretion and Clearance

Both peptides undergo proteolytic degradation to constituent amino acids, which re-enter normal metabolic pools. No specific organ accumulation has been documented in published studies. Renal and hepatic clearance pathways are involved in fragment elimination, consistent with other peptides of similar size. CJC-1295 NO DAC fragments resulting from protease cleavage lack significant biological activity due to the requirement for intact N-terminal structure for GHRH receptor binding.

The complementary pharmacokinetics of the two peptides create distinct temporal GH stimulation profiles that researchers use to model physiological pulsatility. Ipamorelin’s rapid onset and 2-hour duration generates the acute pulse, while CJC-1295 NO DAC’s 2-hour sustained elevation maintains amplified baseline GH secretion across the same window.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data

• No published Phase II or III human trials for the blend specifically
• CJC-1295 clinical data uses the DAC version almost exclusively; NO DAC human pharmacokinetics remain poorly characterized
• Ipamorelin human data limited to early-phase pharmacokinetic and pharmacodynamic studies with small sample sizes
• Safe and effective dosing parameters for humans are unknown for the blend
• Long-term safety of sustained GH and IGF-1 elevation through secretagogue use is unstudied in human subjects

Mechanistic Understanding

• The 3- to 5-fold synergistic GH release figure derives primarily from animal models and in vitro work; precise quantification in humans has not been established
• Optimal blend ratios, timing intervals, and dosing frequencies for maximizing pulsatile GH release without receptor desensitization have not been established in controlled studies
• Long-term receptor sensitization and desensitization dynamics with repeated blend administration are unknown
• Potential interactions between the two intracellular signaling pathways at the somatotroph level need dedicated mechanistic investigation

Methodological Considerations

• Most blend research extrapolates from individual peptide studies rather than directly studying the combination
• Variation in animal model species, ages, and health status limits cross-study comparisons
• Many preclinical studies use rodent models with GH-deficient or otherwise abnormal GH axes, limiting applicability to normal physiology
• Publication bias toward positive findings likely affects the available evidence base
• Effects on insulin sensitivity, glucose metabolism, and other downstream GH targets have not been comprehensively characterized for the blend

Areas Needing Further Investigation

• Human pharmacokinetic studies specifically for CJC-1295 NO DAC: the NO DAC version lacks the clinical data that exists for the DAC variant
• Dedicated blend studies: most current evidence is extrapolated from individual peptide research
• Long-term safety of elevated GH and IGF-1 beyond 28-day observation windows: completely uninvestigated for the blend
• Effects in specific populations: older adults, individuals with metabolic dysfunction, and other groups where GH axis changes are clinically relevant
• Comparison studies against exogenous GH administration to quantify whether secretagogue-driven GH elevation produces equivalent or distinct biological outcomes

Regulatory and Research Status

Current Classification

FDA Status Both CJC-1295 NO DAC and Ipamorelin are classified as unapproved new drugs under FDA jurisdiction. Neither has received approval for human therapeutic use. The FDA has not issued compound-specific guidance documents for either peptide, placing them in a research chemical category. Legitimate laboratory research applications require compliance with applicable regulations governing research peptide procurement and use.

WADA Status Both peptides appear on the World Anti-Doping Agency prohibited list under the category of peptide hormones, growth factors, related substances, and mimetics. All compounds in this category are prohibited in-competition and out-of-competition for athletes subject to anti-doping testing. The prohibited status applies regardless of administration route or dosing parameters. Researchers working with athletes or study populations subject to anti-doping regulations must account for this classification.

International Perspective The European Medicines Agency has not approved either compound for human therapeutic use. Most major international regulatory jurisdictions follow similar research-only classifications. Veterinary application regulations vary by country. The regulatory status for both compounds reflects the absence of completed Phase III clinical trial data required for therapeutic approval pathways.

Research Community Approach

University-based preclinical research continues across North America, Europe, and Asia, primarily funded through basic science and endocrinology grants. Institutional biosafety and animal care committees oversee legitimate research use. The absence of patent protection with clear commercial pathways has limited pharmaceutical industry investment in advancing either compound through full clinical development, despite the availability of clinical data for CJC-1295 (DAC version) demonstrating safety and efficacy signals in Phase I/II studies.

Future Research Directions

The most significant gap is a well-designed human pharmacokinetic and safety study for CJC-1295 NO DAC specifically, followed by blend combination studies. The existing CJC-1295 DAC clinical data provides a regulatory precedent for safety assessment methodology. Researchers identify the preservation of pulsatile GH secretion as the key differentiating feature of the NO DAC blend approach compared to continuous GH secretagogue stimulation, and this physiological rationale supports further clinical investigation.

Key Research Findings

CJC-1295 Human Phase I/II Dose-Response Study

Research Focus: Safety, pharmacokinetics, and GH/IGF-1 response to CJC-1295 (DAC version) in healthy adults Key Results: Single doses of 30 to 90 mcg/kg elevated GH 2- to 10-fold within 2 hours; IGF-1 increased 1.5- to 3-fold for 9 to 11 days; repeated weekly dosing sustained IGF-1 elevation for up to 28 days; no serious adverse events reported across 64 subjects Significance: Establishes clinical proof-of-concept for GHRH analog-driven GH and IGF-1 elevation in humans; provides the primary human safety and efficacy dataset for the CJC-1295 compound class Limitations: Studies used the DAC version; NO DAC version has not been studied with equivalent rigor; sample size modest for safety conclusions [1]

Pulsatile Secretion Preservation During Continuous CJC-1295 Stimulation

Research Focus: Whether natural GH pulsatility is maintained during sustained GHRH analog exposure Key Results: Pulsatile GH secretion persisted throughout continuous CJC-1295 stimulation in human subjects; episodic peaks were maintained alongside elevated GH baseline Significance: Resolves a key theoretical concern that sustained GHRH receptor stimulation would abolish physiological pulsatility; supports the rationale for using GHRH analogs over exogenous GH Limitations: Study used DAC version; pulsatility characteristics with the shorter-acting NO DAC version may differ [7]

Ipamorelin GH Selectivity in In Vitro and Animal Models

Research Focus: Receptor selectivity of Ipamorelin compared to other growth hormone secretagogues Key Results: Ipamorelin produced dose-dependent GH release with EC50 approximately 1.3 nmol/L; no significant effect on ACTH, cortisol, prolactin, FSH, or TSH at GH-effective doses; selectivity profile substantially better than GHRP-2 or GHRP-6 Significance: Establishes Ipamorelin as a highly selective GH research tool; selectivity enables attribution of observed biological effects specifically to GH axis activation rather than broader hormonal changes Limitations: Primary selectivity data from in vitro cell models and rodent studies; comprehensive human selectivity data limited [2]

Ipamorelin Bone Growth and Anti-Glucocorticoid Effects

Research Focus: Ipamorelin effects on longitudinal bone growth and glucocorticoid-induced bone suppression in rat models Key Results: Dose-dependent bone growth rate increases from 42 to 52 micrometers per day; partial restoration of bone mineral content following glucocorticoid-induced suppression Significance: Provides mechanistic basis for studying GH secretagogues in bone loss conditions; demonstrates that pituitary-level GH stimulation translates to skeletal outcomes at the tissue level Limitations: Rodent models only; glucocorticoid dose and timing used in these studies may not reflect clinical conditions [8,9]

Synergistic GH Amplification in Combination Models

Research Focus: Quantification of GH release with combined CJC-1295 and Ipamorelin administration versus individual peptides Key Results: Combined administration produced 3- to 5-fold greater GH release than either peptide alone in animal models; 2025 pharmacological review reported 7.5-fold pulse amplitude increase with combination; complementary temporal profiles confirmed: Ipamorelin peak at 40 to 60 minutes, CJC-1295 NO DAC sustained elevation over 4 to 6 hours Significance: Provides quantitative rationale for blend approach over single-peptide administration; dual-pathway architecture confirmed as pharmacologically synergistic rather than merely additive Limitations: Synergistic figures derive from animal models and pharmacological modeling; human equivalent data does not exist [4,5]

IGF-1 Sustained Elevation and Downstream Anabolic Signaling

Research Focus: Duration and magnitude of IGF-1 elevation following CJC-1295 and Ipamorelin administration Key Results: CJC-1295 single doses elevated IGF-1 1.5- to 3-fold for 9 to 11 days; repeated dosing extended IGF-1 elevation to 28 days; downstream activation of JAK-STAT5 signaling in liver confirmed as primary mediator Significance: Demonstrates that pituitary-level GH stimulation produces sustained downstream IGF-1 responses with potential applications in research on anabolic signaling, bone metabolism, and tissue repair Limitations: IGF-1 data from CJC-1295 DAC studies; NO DAC version produces shorter duration IGF-1 elevation; downstream anabolic effects in specific tissues extrapolated from IGF-1 biology rather than direct blend studies [1,6]

Frequently Asked Questions

What is the difference between CJC-1295 NO DAC and CJC-1295 DAC?

The two versions of CJC-1295 differ primarily in duration of action. The DAC version includes a Drug Affinity Complex that allows the peptide to bind albumin in the bloodstream, extending its half-life to approximately 6 to 8 days. The NO DAC version lacks this modification and has a much shorter half-life of 30 minutes to 2 hours. Researchers studying pulsatile GH secretion patterns typically use the NO DAC version because its shorter action window allows dose-by-dose control over GH stimulation timing.

Why do researchers study CJC-1295 NO DAC and Ipamorelin together?

The two peptides activate entirely different receptor systems in the pituitary gland. CJC-1295 NO DAC stimulates GHRH receptors, while Ipamorelin activates ghrelin receptors (GHS-R1a). Because these pathways use different intracellular messengers, co-administration engages both simultaneously, producing GH release that animal studies suggest is 3 to 5 times greater than either peptide alone while still maintaining the natural pulsatile character of GH secretion.

What makes Ipamorelin different from other growth hormone secretagogues like GHRP-6?

Ipamorelin is notable for its selectivity. Most older growth hormone secretagogues in the same class, including GHRP-2 and GHRP-6, stimulate the release of cortisol and prolactin alongside growth hormone. Ipamorelin produces GH release without significant changes in these other hormones at research-effective doses. This selectivity makes it easier for researchers to attribute observed biological effects specifically to GH axis activation rather than to broader hormonal changes.

What is the current state of human research on this blend?

Human clinical data is limited primarily to CJC-1295 (DAC version) studies, where Phase I/II trials in healthy adults demonstrated dose-dependent GH and IGF-1 increases with no serious adverse events. Ipamorelin has limited early-phase human pharmacokinetic data. The specific combination of CJC-1295 NO DAC and Ipamorelin has not been studied in completed human clinical trials. Most evidence supporting the blend rationale comes from animal models and pharmacological modeling.

Is the CJC-1295 NO DAC and Ipamorelin blend approved for any use?

Neither peptide is approved for human therapeutic use by the FDA, EMA, or other major regulatory agencies. Both are classified as research-use-only compounds. Both peptides also appear on the World Anti-Doping Agency prohibited list, meaning athletes subject to anti-doping testing are prohibited from using either compound. Any legitimate application involves laboratory research under appropriate institutional oversight.

References

1. Teichman, S.L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.P., & Frohman, L.A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805. PubMed

2. Raun, K., Hansen, B.S., Johansen, N.L., Thogersen, H., Madsen, K., Ankersen, M., & Andersen, P.H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. PubMed

3. Gobburu, J.V., Bhatt, B.D., Ramanathan, M., Bhatt, S., Bhatt, D., & DeSante, K.A. (1999). Pharmacokinetics and pharmacodynamics of ipamorelin, a growth hormone releasing peptide, in healthy volunteers. European Journal of Pharmaceutical Sciences, 9(3), 261-268. PubMed

4. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J.P., Frohman, L.A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology: Endocrinology and Metabolism, 291(6), E1290-E1294. PubMed

5. Devesa, J., Almenglo, C., & Devesa, P. (2025). Growth hormone secretagogues: molecular and clinical pharmacology review. Frontiers in Endocrinology, 16, 1478892. PubMed

6. Frohman, L.A., & Kineman, R.D. (2002). Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis. Trends in Endocrinology and Metabolism, 13(7), 299-303. PubMed

7. Ionescu, M., & Frohman, L.A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, 91(12), 4792-4797. PubMed

8. Johansen, P.B., Segev, Y., Landau, D., Shapiro, R., & Phillip, M. (1999). Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue. European Journal of Endocrinology, 140(6), 548-555. PubMed

9. Andersen, N.B., Malmlof, K., Johansen, P.B., Andreassen, T.T., Ortoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone and IGF Research, 11(5), 266-272. PubMed

10. Nass, R., Pezzoli, S.S., Oliveri, M.C., Patrie, J.T., Harrell, F.E., Clasey, J.L., Heymsfield, S.B., Bach, M.A., Vance, M.L., & Thorner, M.O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601-611. PubMed

11. Veldhuis, J.D., Bowers, C.Y., & Iranmanesh, A. (2003). Growth hormone-releasing peptide-2 infusion synchronizes growth hormone release with prolactin and thyroid-stimulating hormone secretion in women. Journal of Clinical Endocrinology and Metabolism, 88(3), 1263-1272. PubMed

12. Trejo, J.L., Carro, E., & Torres-Aleman, I. (2001). Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. Journal of Neuroscience, 21(5), 1628-1634. PubMed

13. Jeschke, M.G., Herndon, D.N., Wolf, S.E., DebRoy, M.A., Stein, H.G., & Barrow, R.E. (1999). Recombinant human growth hormone alters acute phase reactant proteins, cytokine expression, and liver morphology in burned rats. Journal of Surgical Research, 83(2), 122-129. PubMed

14. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656-660. PubMed

15. Prakash, A., & Goa, K.L. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2), 139-157. PubMed

16. Smith, R.G., Sun, Y., Betancourt, L., & Asnicar, M. (2004). Growth hormone secretagogues: prospects and potential pitfalls. Best Practice and Research: Clinical Endocrinology and Metabolism, 18(3), 333-347. PubMed

17. Svensson, J., Lall, S., Dickson, S.L., Bengtsson, B.A., Romer, J., Ahnfelt-Ronne, I., Ohlsson, C., & Jansson, J.O. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology, 165(3), 569-577. PubMed